Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Burixafor - TaiGen Biotechnology

Next Previous
Drug Profile

Burixafor - TaiGen Biotechnology

Alternative Names: TG-0054

Latest Information Update: 24 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TaiGen Biotechnology
  • Class Anti-ischaemics; Eye disorder therapies; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stem cell mobilisation
  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2018 Burixafor is still in phase I/II trials for Stem cell mobilisation (for chemosensitisation in haematological malignancies) in China (IV) (TaiGen Biotechnology pipeline, January 2018)
  • 24 Jan 2018 Burixafor is still in phase II trials for Stem cell mobilisation in USA (IV) (TaiGen Biotechnology pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top